Amcor Completes One-for-Five Reverse Stock Split

Rhea-AI Summary

10x Genomics (Nasdaq: TXG) launched Chromium Xo, a lower‑cost single cell instrument priced at a U.S. list of $25,000 and now shipping globally. Chromium Xo is designed to run the GEM‑X 3' assay, which the company says delivers up to 80% cell capture and >40% higher gene sensitivity versus non‑10x methods. GEM‑X also enables more usable reads to detect more genes with less sequencing, potentially saving more than 50% on sequencing costs compared to alternatives. The instrument offers automation for high throughput, a push‑button interface, and an upgrade path to Chromium X for expanded assays including FFPE and immune profiling. Management stated a goal of enabling high‑performance single cell analysis for $100 per sample over time.

Key Figures

Chromium Xo price: $25,000 Cell capture rate: 80% Gene sensitivity uplift: 40% +2 more

5 metrics

Chromium Xo price $25,000 U.S. list price for single cell instrument

Cell capture rate 80% GEM-X 3' assay maximum cell capture

Gene sensitivity uplift 40% Higher gene sensitivity vs non-10x methods

Sequencing cost savings 50% Potential savings vs non-10x methods

Target cost per sample $100 Goal for high-performance single cell analysis per sample

Market Reality Check

Price: $8.82 Vol: Volume 20,290,336 is slig...

normal vol

$8.82 Last Close

Volume Volume 20,290,336 is slightly above the 20-day average of 17,582,218. normal

Technical Trading near its 200-day MA at 8.8, indicating a largely trend-aligned position pre-split.

Peers on Argus

Peers show mixed moves: positives for PKG, BALL, AVY and negatives for SW, IP. N...

Peers show mixed moves: positives for PKG, BALL, AVY and negatives for SW, IP. No momentum scanner confirmation of a coordinated sector move.

Historical Context

5 past events · Latest: Dec 11 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 11	Reverse split plan	Neutral	-1.2%	Announced timing and mechanics of 1-for-5 reverse stock split.
Nov 18	Innovation initiative	Positive	+0.1%	Launched Lift-Off challenge to source sustainable packaging technologies.
Nov 05	Quarterly earnings	Positive	+2.5%	Reported strong Q1 growth, synergies and reaffirmed fiscal 2026 guidance.
Oct 27	Sustainability report	Positive	+1.6%	Released FY25 sustainability metrics showing progress on circularity and emissions.
Oct 22	Earnings scheduling	Neutral	+1.1%	Announced timing and access details for Q1 2026 results call.

Pattern Detected

Recent news with clearly positive fundamentals (earnings, sustainability progress) saw modestly positive price reactions, while the earlier reverse split announcement drew a small decline.

Recent Company History

Over the last few months, Amcor reported strong combined Q1 results with $5,745M net sales and $909M adjusted EBITDA, reaffirmed fiscal 2026 guidance, and raised its quarterly dividend. Sustainability reporting highlighted progress on circularity, emissions and recyclability, while innovation programs like Amcor Lift-Off targeted more sustainable packaging technologies. The prior 1-for-5 reverse split announcement on Dec 11, 2025 produced a modest -1.2% move, providing the key historical reference for today’s reverse split completion.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2025-07-15

The company has an active S-3ASR shelf registration dated 2025-07-15, effective through 2028-07-15, with 0 recorded usages to date. This provides pre-cleared flexibility to issue securities if the company chooses, but no usage has been disclosed in the provided data.

Market Pulse Summary

This announcement completes Amcor’s previously outlined 1-for-5 reverse stock split, following share...

Analysis

This announcement completes Amcor’s previously outlined 1-for-5 reverse stock split, following shareholder approval and the effective date set in December 2025. It is a largely mechanical step that consolidates shares while leaving recent fundamentals—such as strong Q1 results and reaffirmed fiscal 2026 guidance—unchanged. Investors may focus on how split-adjusted metrics are reported, any impacts on trading liquidity, and how this action fits alongside the company’s existing S-3ASR flexibility and recent governance decisions.

Key Terms

single cell analysis, spatial biology, ffpe

3 terms

single cell analysis medical

"Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis."

A laboratory method that examines individual cells one by one to measure their genes, proteins or activity, rather than averaging results across many cells. For investors, it matters because this fine-grained view can reveal hidden subpopulations, pinpoint more precise drug targets, improve diagnostic tests and reduce development risk—think of inspecting each brick in a wall to find the ones that need repair instead of judging the wall as a whole.

spatial biology medical

"10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo,"

Spatial biology maps where different cells and molecules sit inside tissues, like a detailed city map showing not just who lives in a neighborhood but where every house and shop is located. For investors, those location details can reveal how diseases start and respond to treatments, guiding new drugs, diagnostics, and lab tools that can change clinical success rates and create commercial opportunities.

ffpe medical

"upgrade to Chromium X to access the full breadth of the company's single cell portfolio, including assays for FFPE samples and immune profiling."

FFPE stands for formalin-fixed, paraffin-embedded, a standard laboratory method for preserving tissue samples by chemically fixing them and enclosing them in wax so they keep their structure over time. Think of it like embedding a pressed flower in wax to preserve its shape and details. For investors, FFPE matters because many diagnostic tests, drug development studies and biomarker analyses rely on these preserved samples; their quality and compatibility with laboratory assays affect clinical validation, regulatory approval and the commercial value of pathology and diagnostics products.

AI-generated analysis. Not financial advice.

PLEASANTON, Calif., Sept. 3, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis.

"Chromium Xo is the latest in a series of 10x innovations intended to democratize single cell analysis because we never want researchers to have to settle for anything less than the best," said Ben Hindson, Chief Scientific Officer and Co-founder. "With Chromium Xo, we're not just lowering the cost barrier; we're empowering more researchers to achieve high-quality, repeatable results necessary for meaningful scientific breakthroughs."

Chromium Xo is 10x Genomics' most affordable single cell instrument, delivering the high-quality data, superior reproducibility and ease of use that the company's instrument-powered workflows are known for, at a U.S. list price of $25,000.

Chromium Xo is specifically designed to run 10x Genomics' industry-leading GEM-X 3' assay, which provides up to 80% cell capture and more than 40% higher gene sensitivity compared to alternative non-10x methods. GEM-X technology also enables researchers to generate more usable reads to detect more genes with less sequencing, potentially saving more than 50% on sequencing costs compared to non-10x methods.

In addition, there is a path for researchers to seamlessly upgrade to Chromium X to access the full breadth of the company's single cell portfolio, including assays for FFPE samples and immune profiling.

With features like automation to partition hundreds of thousands of cells in minutes and an intuitive push-button interface for efficient cell processing, Chromium instruments remove many of the challenges and inconsistencies of manual, instrument-less workflows. The instrument-powered Chromium platform enables high data quality and twice the sample recovery as manual methods. In addition, Chromium instruments streamline the workflow, improve scalability and enable superior reproducibility, resulting in less hands-on time, lower labor and experimental costs and faster time to results compared to alternative single cell workflows.

Added Hindson, "Our ultimate goal is to enable high-performance single cell analysis for $100 per sample. With Chromium Xo and what's planned in our pipeline, we are continuing to drive our Chromium technology in that direction so more researchers can rely on these methods more often."

Chromium Xo is now shipping globally.

About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the "safe harbor" provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "see," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding 10x Genomics, Inc.'s ("10x Genomics") and others' product launches, performance, configuration, costs, capabilities, requirements, workflows, adoption and pipeline. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics' financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the "SEC") from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics' views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-unveils-chromium-xo-a-low-cost-instrument-to-expand-access-to-high-performance-single-cell-research-302237175.html

SOURCE 10x Genomics, Inc.

FAQ

What is Chromium Xo and who makes it (ticker TXG)?

Chromium Xo is a lower‑cost single cell instrument launched by 10x Genomics (Nasdaq: TXG) designed for routine, high‑performance single cell analysis.

How much does the 10x Genomics Chromium Xo cost and is it available now?

Chromium Xo has a U.S. list price of $25,000 and the company says it is now shipping globally.

What performance claims does the GEM‑X 3' assay on Chromium Xo make?

The GEM‑X 3' assay is reported to provide up to 80% cell capture and >40% higher gene sensitivity versus non‑10x methods.

Does Chromium Xo reduce sequencing costs for users?

The company reports GEM‑X can generate more usable reads and may save more than 50% on sequencing costs compared to non‑10x methods.

Can users upgrade Chromium Xo to other Chromium platforms or assays?

Yes. There is a stated upgrade path to Chromium X to access additional assays including FFPE sample support and immune profiling.

What is 10x Genomics' stated long‑term cost goal per sample with Chromium technology?

Management stated a goal to enable high‑performance single cell analysis for $100 per sample over time.